| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8755192 | Auris Nasus Larynx | 2015 | 5 Pages |
Abstract
The efficacy of modified TPF in the setting of first-line treatment for recurrent or metastatic HNSCC is not very high, while the toxicity is acceptable with extensive care. The development of more efficacious chemotherapeutic regimen is required.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Hironori Cho, Suetaka Nishiike, Yoshifumi Yamamoto, Yukinori Takenaka, Susumu Nakahara, Toshimichi Yasui, Atsushi Hanamoto, Hidenori Inohara,